<?xml version="1.0" encoding="UTF-8"?>
<p>Although IFN did not change the time to reach a clinical response, added to the national protocol, it significantly increased the discharge rate on day 14 and decreased 28-day mortality. Improved survival rate was significant when patients received IFN β-1a in the early phase of the disease. Adverse effects of IFN β-1a were injection-related, neuropsychiatric problems, and hypersensitivity reactions that all were tolerable and resolved during the follow-up period.</p>
